drugset
drugset / Trial / NCT03546608

Tepotinib Hepatic Impairment Trial

NCT03546608 ↗

Phase 1 Completed 18 enrolled EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelOther

Summary

The study investigated the effect of various degrees of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of tepotinib.

Timeline

Start
2018-06-13
Primary completion
2019-02-05
Completion
2019-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tepotinib Small molecule 500 mg Oral

Indications

No indication recorded.